Mediran

Ranitidine, the active ingredient in Mediran, is a Histamine H2‑receptor antagonist presented as an oral tablet for oral use. It reduces gastric acid production and is employed in the management of ulcer‑related and reflux disorders in adult patients.\n\nGNH India supplies Mediran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ranitidine acts on the histamine H2‑receptor pathway to lower gastric acidity, making it useful for several acid‑related gastrointestinal conditions.\n\n- Peptic ulcer disease: promotes ulcer healing by decreasing acid secretion.\n- Gastroesophageal reflux disease (GERD): relieves heartburn and esophageal irritation.\n- Erosive esophagitis: facilitates mucosal recovery by limiting acid exposure.\n- Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Adverse reactions may range from mild to severe and should be monitored during therapy.\n\nCommon Side Effects:\n- Headache: mild to moderate intensity.\n- Dizziness: transient sensation of light‑headedness.\n- Nausea: occasional upset stomach.\n- Diarrhoea: loose stools, usually self‑limiting.\n- Constipation: reduced bowel movements.\n- Fatigue: feeling of tiredness or lack of energy.\n\nSerious or Rare Side Effects:\n- Hepatotoxicity: signs of liver injury such as jaundice.\n- Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.\n- Thrombocytopenia: low platelet count leading to easy bruising.\n- Neutropenia: reduced neutrophil count increasing infection risk.\n- Anaphylaxis: acute allergic reaction with airway compromise.\n- Cardiac arrhythmia: irregular heart rhythm in susceptible individuals.

Before initiating therapy, clinicians should consider several safety factors.\n\n- Assess renal function: dose adjustment may be required in impairment.\n- Avoid in known hypersensitivity: discontinue if rash or angio‑edema occurs.\n- Use caution in hepatic disease: monitor liver enzymes periodically.\n- Monitor electrolytes: especially when combined with diuretics.\n- Pregnancy and lactation: evaluate risk‑benefit ratio before prescribing.\n- Store at below 25°C: keep in the original pack, protect from moisture.

Ranitidine can alter the pharmacokinetics of several co‑administered drugs.\n\nMajor Interactions (Avoid):\n- Cimetidine: additive H2‑blockade may cause excessive acid suppression.\n- Ketoconazole: reduced absorption due to higher gastric pH.\n- Atorvastatin: increased plasma concentrations, raising risk of myopathy.\n- Clopidogrel: diminished activation leading to reduced antiplatelet effect.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: possible increase in INR, requiring closer coagulation monitoring.\n- Theophylline: elevated serum levels may precipitate toxicity.\n- Diazepam: enhanced sedative effect, warranting dose review.